- POSITIVE
Quarterly Revenue Sai Parenterals Jun-2026 Quarterly Revenue is Rs 56 Cr which is growth of 174.9% YoY.
- POSITIVE
Quarterly Net Profit Sai Parenterals Jun-2026 Quarterly Net Profit is Rs 9 Cr which is growth of 975.9% YoY.
Sai Parenterals Ltd.
NSE: SAIPARENT | BSE: 544742Sai Parenterals Live Share Price Today, Share Analysis and Chart
aboutSai Parenterals Ltd. is a pharmaceutical company headquartered in Hyderabad, India. The company focuses on the development, manufacturing, and supply of parenteral products (injectables) and other pharmaceutical formulations. Recently listed on the I... Read More
521.9516.25(3.21%)
278.1K
NSE+BSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Slowing Down StockThese stocks have medium financials and valuations, but weak momentum indicating decreasing investor interestView SimilarEmbed DVM
Please subscribe to view forecaster data
Sai Parenterals Stock Price Analysis
Day Price Range3.2% 1 Day return | 522 (LTP) 500.4531.4 LowHigh |
|---|---|
Week Price Range13.0% 1 Week return | 522 (LTP) 450531.4 LowHigh |
Month Price Range-1.4% 1 Month return | 522 (LTP) 441.4535 LowHigh |
52 Week Price Range33.2% 1 Year return | 522 (LTP) 400706 LowHigh |
Competitors/Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Sai Parenterals quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 |
|---|---|---|---|---|---|---|
| 56.2 | 56.9 | 39.2 | 48.4 | 20.4 | ||
Operating Exp. | 39.4 | 43.6 | 34.5 | 37.4 | 16.2 | |
Operating Profit | 13.4 | 13.2 | 4 | 10.4 | 3 | |
Operating Profit Margin % | 25.30% | 23.29% | 10.33% | 21.67% | 15.76% | |
Depr. | 1.4 | 1.5 | 1.6 | 1.3 | 1.3 | |
Interest | 3.6 | 3.4 | 2.1 | 1.5 | 1.8 | |
Profit Before Tax | 11.8 | 8.4 | 1 | 8.2 | 1.2 | |
Tax | 3 | -1.5 | 0.6 | 2.5 | 0.4 | |
Net Profit | 8.9 | 10 | 0.4 | 5.6 | 0.8 | |
EPS Adj. latest | 2 | 2.3 | 0.1 | 1.3 | 0.2 | |
Net profit TTM | 24.8 | 16.8 | - | - | - | |
Basic EPS TTM | 5.6 | 3.8 | - | - | - | |
Earnings Transcripts | ||||||
Results PDF | ||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Sai Parenterals Technical Analysis
Sai Parenterals EMA & SMA
Bullish+7
7 bullish, 0 bearish
Bullish7
Bearish0
| 5 Day | 497 |
|---|---|
| 10 Day | 489.6 |
| 12 Day | 489.3 |
| 20 Day | 492.0 |
| 26 Day | 495.2 |
|---|---|
| 50 Day | 506.5 |
| 100 Day | 512.2 |
Sai Parenterals Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 202648.1%
Week51.0%
Month54.4%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Sai Parenterals Resistance and Support
517.92
Pivot
| First Resistance | 535.5 |
|---|---|
| Second Resistance | 549.0 |
| Third Resistance | 566.6 |
| First Support | 504.4 |
|---|---|
| Second Support | 486.8 |
| Third Support | 473.3 |
| Day RSI | 59.1 |
|---|---|
| Day MACD | -5.9 |
| Day MFI | 64.1 |
| Day MACD Signal Line | -10.4 |
Sai Parenterals Beta
| 1 Month | 0.4 |
|---|---|
| 1 Year | - |
| 3 Month | 0.6 |
|---|---|
| 3 Year | - |
Sai Parenterals Price Change Analysis
↓-1.4%
Over 1 Month
LowHigh
441.4535
↓-4.7%
Over 3 Months
LowHigh
441.4594
↑7.4%
Over 6 Months
LowHigh
441.4706
↑33.2%
Over 1 Year
LowHigh
400706
Sai Parenterals Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| HRTI PRIVATE LIMITED | Bulk | Sell | 02 Jul 2026 | 637.95 | 226,834 | NSE |
| HRTI PRIVATE LIMITED | Bulk | Purchase | 02 Jul 2026 | 639.68 | 105,392 | NSE |
| ARIHANT CAPITAL MARKETS LIMITED | Bulk | Purchase | 09 Apr 2026 | 423.13 | 398,007 | NSE |
| BHASKARA RAO BOLLINENI | Bulk | Purchase | 07 Apr 2026 | 409.25 | 512,241 | NSE |
| ARIHANT CAPITAL MARKETS LIMITED | Bulk | Purchase | 02 Apr 2026 | 407.60 | 451,212 | BSE |
Sai Parenterals Corporate Actions
Sai Parenterals Board Meetings
Sai Parenterals past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
101 Nov 2026 | Quarterly Results | - |
211 Aug 2026 | Quarterly Results | - |
323 May 2026 | Audited Results & Others | To consider other business matters. |
420 Apr 2026 | Others | Inter-alia, to consider 1. Proposal to invest in/ lend to Noumed Pharmaceuticals Pty Limited, Australia, a step-down subsidiary of the Company. 2. Other business matters. |
Sai Parenterals Research Reports
Sai Parenterals research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 123 Mar 2026 | Hem Securities | - | - | IPO Subscribe | - | -% | |
| 222 Mar 2026 | Deven Choksey | - | - | IPO Note | - | -% | |
| 322 Mar 2026 | Ventura | - | - | IPO Subscribe | - | -% | |
| 419 Mar 2026 | SBI Securities | - | - | IPO Subscribe | - | -% | |
| 519 Mar 2026 | ICICI Direct | - | - | IPO Note | - | -% |
Sai Parenterals Corporate Filings
Sai Parenterals BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 01 Nov 2026 | Sai Parenterals Ltd - 544742 - Unaudited Financial Results For The Quarter And Half-Year Ended September 30Th 2026. | Unaudited financial results for the quarter and half-year ended September, 30th 2026. | |
| 01 Nov 2026 | Sai Parenterals Ltd - 544742 - Board Meeting Outcome for Outcome Of Board Meeting Held On 1St November, 2026 | Outcome of Board Meeting held on 1st November, 2026 | |
| 28 Oct 2026 | Sai Parenterals Ltd - 544742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | Schedule of Q2 of FY 2026-27 Earnings Conference Call. | |
| 27 Oct 2026 | Sai Parenterals Ltd - 544742 - Board Meeting Intimation for Declaration Of Unaudited Financial Results Of The Quarter And Half Year Ended 30Th September, 2026. | Sai Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2026 ,inter alia, to consider and approve unaudited financial results of the quarter and half year ended 30th September, 2026. | |
| 08 Oct 2026 | Sai Parenterals Ltd - 544742 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | RTA''s Certificate |
Sai Parenterals Documents
Sai Parenterals Earnings Call
Sai Parenterals earnings calls, including management commentary and AI-generated summaries.
| Date | Title | Links |
|---|---|---|
| 18 Aug 2026 | Sai Parenterals Ltd - 544742 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
| 12 Aug 2026 | Sai Parenterals Ltd - 544742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Link |
| 29 May 2026 | Sai Parenterals Ltd - 544742 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
Sai Parenterals Annual Reports
Sai Parenterals financials, including annual results, balance sheets, and cash flow statements.
| Date | Report Title | Links |
|---|---|---|
| 2026 | Annual Report Mar-2026 | Link |
Sai Parenterals Investor Presentations
Sai Parenterals investor presentations, including business updates, financial insights, and strategic initiatives.
Sai Parenterals - Company Profile
Sai Parenterals Management Structure
Sai Parenterals management structure with salaries, total experience, and qualifications.
Sai Parenterals Board of Directors
Sai Parenterals Board of directors with salaries, total experience, and qualifications.
Website: www.saiparenterals.com
About the company - Business Profile
Sai Parenterals Ltd. is a pharmaceutical company headquartered in Hyderabad, India. The company focuses on the development, manufacturing, and supply of parenteral products (injectables) and other pharmaceutical formulations. Recently listed on the Indian stock exchanges in April 2026, the company operates within the specialized niche of sterile injectables and large-volume parenterals.
Key Points
- Key Facts:
- Stock Listing: Listed on BSE (Scrip Code: 544742) and NSE (Symbol: SAIPARENT) effective April 2, 2026.
- Headquarters: Plot No. 39, 6th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad - 500032.
- Key Management: Anil Kumar Karusala (Chairman and Managing Director).
- Operations and Resources:
- The company maintains manufacturing facilities specializing in sterile parenterals.
- It recently expanded its global footprint through acquisitions, notably Noumed Pharmaceuticals PTY Limited, Australia (acquired on November 12, 2025, as a step-down subsidiary via Sai Singapore Pte. Ltd.).
- Market and Significance:
- Operates in the high-barrier sterile injectable market.
- The company serves both domestic and international markets, including recent expansion into the Australian pharmaceutical sector.
- Business Model:
- Sai Parenterals operates as a formulation manufacturer with a focus on science, affordability, and innovation.
- Its model includes direct product manufacturing and likely contract development and manufacturing (CDMO) services, given its expansion into regulated markets like Australia.
- Revenue and Financials:
- As a newly listed entity (April 2026), the company is in the process of finalizing its first post-listing annual results.
- Management indicated that audited financial results for the year ended March 31, 2026, are expected to be published by May 30, 2026.
- Consolidation includes international operations from Singapore and Australia.
- Key Products and Technology:
- Core offerings include Parenterals (injectable drugs), which require sterile manufacturing environments.
- The acquisition of Noumed Pharmaceuticals adds a portfolio of products tailored for the Australian and potentially other regulated markets.
- Strategic Initiatives and Future Outlook:
- Global Expansion: The acquisition of Noumed Pharmaceuticals PTY Limited marks a significant move into the Australian market.
- Transparency: Post-IPO, the company has committed to upholding SEBI listing regulations and transparency standards, despite initial administrative delays in reporting due to international subsidiary audits.